Sunesis to Present at the 2016 UBS Global Healthcare Conference
May 18 2016 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that
Daniel Swisher, Chief Executive Officer of Sunesis, will present at
the 2016 UBS Global Healthcare Conference on Wednesday, May 25th at
11:00 AM Eastern Time at The Grand Hyatt in New York City.
A live webcast of the presentation will be
available on the Sunesis website at http://ir.sunesis.com. A replay
of the webcast will be archived on the "Calendar of Events" page in
the Investors and Media section of the Sunesis website for two
weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on
the development and commercialization of new oncology therapeutics
for the potential treatment of solid and hematologic cancers.
Sunesis has built a highly experienced cancer drug development
organization committed to improving the lives of people with cancer
and is currently pursuing regulatory approval in Europe for its
lead product candidate, vosaroxin, for the treatment of relapsed or
refractory acute myeloid leukemia in patients aged 60 and older. In
addition, the company is advancing its kinase-inhibitor pipeline of
novel targeted therapies into the clinic.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024